Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514358 · ClinicalTrials.gov registry record
Fluconazole Pharmacokinetics in Infants
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 55
- Enrollment target
NCT00514358: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT00514358 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00514358 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics of fluconazole in infants and evaluate the dose exposure relationship of current fluconazole dosing in infants who are receiving fluconazole for the prevention or treatment of systemic fungal infections.
Primary Outcome
PK blood samples obtained over 3 weeks in infants receiving fluconazole as standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-06 |
What the finished NCT00514358 record still lists
NCT00514358 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00514358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00514358 about?
NCT00514358 is a clinical study titled "Fluconazole Pharmacokinetics in Infants". The purpose of this study is to determine the pharmacokinetics of fluconazole in infants and evaluate the dose exposure relationship of current fluconazole dosing in infants who are receiving fluconazole for the prevention or treatment of systemic fungal infections.
What is the current status of trial NCT00514358?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2005-11. Estimated completion is 2007-06.
Who is sponsoring clinical trial NCT00514358?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia